Drs. Eichenbaum, Barakat, and Vajzovic discuss the most recently approved therapies for the treatment of wet age-related macular degeneration as well as therapies in the pipeline, with an emphasis on tyrosine kinase inhibitors.
This content was captured during a live-virtual symposium. Polling took place during the symposium.
This activity is supported by an independent medical education grant from Ocular Therapeutix.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education 
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
David Eichenbaum, MD
Director of Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor
Morsani College of Medicine
University of South Florida
Tampa, FL
Mark Barakat, MD
Director of Clinical Research
Retina Macula Institute of Arizona
Medical Director
Spectra Eye Institute
Clinical Assistant Professor
University of Arizona College of Medicine - Phoenix
Scottsdale, AZ
Lejla Vajzovic, MD, FASRS
Director, Duke Surgical Vitreoretinal Fellowship Program
Co-Director, Duke Pediatric Retina and Optic Nerve Center
Director, Duke Eye Center Continuing Medical Education
Associate Professor of Ophthalmology with Tenure
Adult and Pediatric Vitreoretinal Surgery and Diseases
Duke University Eye Center
Durham, NC
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
David Eichenbaum, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan, Amaros Medical, Annexon, Apellis Pharmaceuticals, Astellas, Bausch + Lomb, Coherus Biosciences, CorEvitas/Vestrum, Crinetics, EyePoint Pharmaceuticals, Genentech, Kodiak Sciences, Novartis, Ocular Therapeutix, Ocuphire, Opthea, Outlook, RecensMedical, Regeneron, Regenxbio, ReVive, Roche, and Samsara. Grant/Research Support: 4DMT, Aerie Pharmaceuticals, Alexion, Allegenesis Biotherapeutics, Annexon, Astellas, Aviceda, Bayer, EyeBio, EyePoint Pharmaceuticals, Gemini Pharmaceuticals, Genentech, Gyroscope Therapeutics, Ionis Pharmaceuticals, Janssen, Kodiak Sciences, Kyowa Kirin, Mylan, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, OcuTerra, ONL Therapeutics, Opthea, RecensMedical, Regeneron, Regenxbio, Roche, and Unity Biothechnology. Stock/Shareholder: Amaros Medical, Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina. Speaker's Bureau: Alimera Sciences, Allergan, Apellis Pharmaceuticals, Astellas, Bayer, EyePoint Pharmacuticals, Genentech, Iveric Bio, and Regeneron.
Mark Barakat, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum Biotechnologies, Alcon, Alimera Sciences, Allegro Ophthalmics, Allergan, Annexon Biosciences, Apellis Pharmaceuticals, Arctic Vision, Bausch + Lomb, Biocryst, Biogen, CalciMedica, Celltrion, Cencora, Clearside Biomedical, Coherus Biosciences, EyePoint Pharmaceuticals, Genentech, Kodiak Sciences, Janssen, Neurotech Pharmaceuticals, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, Regenxbio, RevOpsis Therapeutics, Roche, and Stealth BioTherapeutics. Grant/Research Support: Adverum Biotechnologies, Annexon Biosciences, CalciMedica, Clearside Biomedical, EyeBio, EyePoint Pharmaceuticals, Gemini Pharmaceuticals, Genentech, Gyroscope Therapeutics, Kanghong/Vanotech, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Perfuse Therapeutics, Regenxbio, ReNeuron, Ribomic, Roche, Stealth BioTherapeutics, and Unity Biotechnology. Shareholder: NeuBase, Oxurion, and RevOpsis Therapeutics. Speaker's Bureau: Alcon, Apellis Pharmaceuticals, Astellas, Bausch + Lomb, Genentech, Novartis, and Regeneron.
Lejla Vajzovic, MD, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Alcon, Alimera Sciences, Apellis Pharmaceuticals, Bausch + Lomb, BMC Medical Education, BVI, Clearside Biomedical, Coherus Biosciences, DORC, Evolve Medical Education, Genentech, Guidepoint, Gyroscope Therapeutics, Iveric Bio, Janssen/Johnson & Johnson Vision, Novartis, Ocugen, Ocular Surgical, OcuTerra, Outlook Therapeutics, Regenxbio, Roche, and Vindico Medical Education. Grant/Research Support: AGTC, Alcon, Aldeyra, Genentech, Gyroscope Therapeutics, Heidelberg Engineering, Janssen/Johnson & Johnson Vision, National Eye Institute, Novartais, Ocular Therapeutix, Regenxbio, and Roche.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Ocular Therapeutix.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Thomas Albini, MD
Roger A. Goldberg, MD, MBA
Dean Eliott, MD
Charles C. Wykoff, MD, PhD, FACS
Thomas Albini, MD
Roger A. Goldberg, MD, MBA
Thomas Albini, MD
Roger A. Goldberg, MD, MBA
Dean Eliott, MD
Charles C. Wykoff, MD, PhD, FACS
